Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:rifaximin
go back to main search page
Accession:CHEBI:75246 term browser browse the term
Definition:A semisynthetic member of the class of rifamycins and non-systemic gastrointestinal site-specific broad spectrum antibiotic. Used in the treatment of traveller's diarrhoea, hepatic encephalopathy and irritable bowel syndrome.
Synonyms:exact_synonym: (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,15-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)furo[2'',3'':7',8']naphtho[1',2':4,5]imidazo[1,2-a]pyridin-25-yl acetate
 related_synonym: Formula=C43H51N3O11;   InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1;   InChIKey=NZCRJKRKKOLAOJ-XRCRFVBUSA-N;   Rifamycin L 105;   Rifamycin L 105SV;   Rifaxidin;   SMILES=CO[C@H]1\\C=C\\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1c(nc5cc(C)ccn15)c4c3C2=O;   Xifaxsan;   rifaximina;   rifaximine;   rifaximinun
 xref: CAS:80621-81-4;   DrugBank:DB01220;   Drug_Central:2379;   HMDB:HMDB0015351;   KEGG:D02554
 xref_mesh: MESH:C042734
 xref: PMID:23092785;   PMID:23095030;   PMID:23183443;   PMID:23216382;   PMID:23273888;   PMID:23274384;   PMID:23275147;   PMID:23303506;   PMID:23314671;   PMID:23340064;   PMID:23389621;   PMID:23445237;   PMID:23526308;   PMID:23556126;   PMID:23565181;   PMID:23589147;   PMID:23640348;   PMID:23653636;   PMID:23740443;   PMID:23798671;   PMID:23843564;   PMID:23877348;   PMID:23922656;   PMID:25214516;   PMID:25339518;   PMID:25565769;   PMID:25586470;   PMID:25641072;   PMID:25835116;   PMID:25867912;   PMID:25932262;   PMID:26028929;   PMID:26043290;   Reaxys:7790802;   Wikipedia:Rifaximin


show annotations for term's descendants           Sort by:
 
rifaximin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 multiple interactions
increases expression
EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ABCB1A mRNA
rifaximin results in increased expression of ABCB1 mRNA
CTD PMID:21141967 PMID:22790967 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ACTA2 actin alpha 2, smooth muscle multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ACTA2 mRNA CTD PMID:22790967 NCBI chr10:88,935,074...88,991,397
Ensembl chr10:88,935,074...88,991,339
JBrowse link
G APOA4 apolipoprotein A4 multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of APOA4 mRNA CTD PMID:22790967 NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304
JBrowse link
G CCL3 C-C motif chemokine ligand 3 multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein] CTD PMID:21599020 NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
JBrowse link
G CD36 CD36 molecule multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CD36 protein CTD PMID:22790967 NCBI chr 7:80,602,207...80,679,277
Ensembl chr 7:80,369,575...80,679,277
JBrowse link
G CFD complement factor D multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CFD mRNA CTD PMID:22790967 NCBI chr19:859,664...863,641
Ensembl chr19:859,664...863,641
JBrowse link
G CIDEC cell death inducing DFFA like effector c multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CIDEC mRNA CTD PMID:22790967 NCBI chr 3:9,866,710...9,880,253
Ensembl chr 3:9,866,711...9,880,255
JBrowse link
G COL1A1 collagen type I alpha 1 chain multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of COL1A1 mRNA CTD PMID:22790967 NCBI chr17:50,184,096...50,201,649
Ensembl chr17:50,184,101...50,201,632
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 increases expression EXP rifaximin results in increased expression of CYP3A4 mRNA CTD PMID:21141967 PMID:27506419 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP3A5 cytochrome P450 family 3 subfamily A member 5 multiple interactions EXP
ISO
[NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA
[Rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of CYP3A11 mRNA
CTD PMID:21599020 PMID:22790967 NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,998
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7A1 protein CTD PMID:22790967 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G CYP7B1 cytochrome P450 family 7 subfamily B member 1 multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7B1 protein CTD PMID:22790967 NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737
JBrowse link
G DGAT2 diacylglycerol O-acyltransferase 2 multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of DGAT2 mRNA CTD PMID:22790967 NCBI chr11:75,768,778...75,801,534
Ensembl chr11:75,759,512...75,801,535
JBrowse link
G FABP2 fatty acid binding protein 2 multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of FABP2 protein CTD PMID:22790967 NCBI chr 4:119,317,250...119,322,138
Ensembl chr 4:119,317,250...119,322,138
JBrowse link
G IFNG interferon gamma multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein] CTD PMID:21599020 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
JBrowse link
G IL10 interleukin 10 multiple interactions ISO [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of IL10 protein CTD PMID:21599020 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G LTA lymphotoxin alpha multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of LTA mRNA CTD PMID:22790967 NCBI chr 6:31,560,550...31,574,324
Ensembl chr 6:31,572,054...31,574,324
JBrowse link
G MPO myeloperoxidase multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein] CTD PMID:21599020 NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of NR1H4 protein CTD PMID:22790967 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions
increases activity
increases expression
increases response to substance
EXP
ISO
4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; 4,4'-hexafluorisopropylidene diphenol metabolite inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased abundance of Triglycerides; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ABCB1A mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ACTA2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of APOA4 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CD36 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CFD mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CIDEC mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of COL1A1 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7A1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7B1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of DGAT2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of FABP2 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of LTA mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of NR1H4 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of PPARG mRNA; [Rifaximin binds to and results in increased activity of NR1I2 protein] which results in decreased susceptibility to Trinitrobenzenesulfonic Acid; bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; Rifaximin binds to and results in increased activity of NR1I2 protein
[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
rifaximin results in increased expression of NR1I2 mRNA
NR1I2 results in increased susceptibility to rifaximin
CTD PMID:21599020 PMID:22291955 PMID:22790967 PMID:27506419 PMID:30408883 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions EXP [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of PPARG mRNA CTD PMID:22790967 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
JBrowse link
G TGFB1 transforming growth factor beta 1 multiple interactions ISO [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of TGFB1 protein CTD PMID:21599020 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
JBrowse link
G TNF tumor necrosis factor multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] CTD PMID:21599020 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 24775
    role 24693
      biological role 24662
        antimicrobial agent 20571
          rifaximin 23
Path 2
Term Annotations click to browse term
  CHEBI ontology 24775
    subatomic particle 24735
      composite particle 24735
        hadron 24735
          baryon 24735
            nucleon 24735
              atomic nucleus 24735
                atom 24735
                  main group element atom 24601
                    p-block element atom 24601
                      carbon group element atom 24393
                        carbon atom 24357
                          organic molecular entity 24357
                            organic group 22763
                              organic divalent group 22742
                                organodiyl group 22742
                                  carbonyl group 22729
                                    carbonyl compound 22729
                                      carboxylic acid 21798
                                        carboacyl group 19584
                                          univalent carboacyl group 19584
                                            carbamoyl group 19016
                                              carboxamide 19016
                                                lactam 8519
                                                  ansamycin 892
                                                    rifamycins 434
                                                      rifaximin 23
paths to the root